New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

270.24 3.14 +1.18%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Johnson & Johnson (JNJ) revenue by segment, product and region

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.